FAQ: Nutriband's $5.3M Warrant Exercise for AVERSA Fentanyl Development
Summary
What is the main announcement from Nutriband Inc.?
Nutriband Inc. has secured $5,306,000 from the exercise of warrants at a strike price of $6.43 to advance the development of AVERSA Fentanyl, their abuse-deterrent fentanyl patch, including supporting remaining clinical work and submission of a New Drug Application to the FDA.
Why is this funding significant for Nutriband?
This funding is crucial as it provides the financial resources needed to complete the clinical development of AVERSA Fentanyl and submit its New Drug Application to the FDA, potentially making it the world’s first opioid patch with abuse deterrent properties.
What is AVERSA Fentanyl and how does it work?
AVERSA Fentanyl is an abuse-deterrent fentanyl patch that incorporates Nutriband’s AVERSA™ technology, designed to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential in transdermal patch form.
What is the market potential for AVERSA Fentanyl?
According to a 2022 Health Advances market analysis report, AVERSA Fentanyl is estimated to reach peak annual U.S. sales of $80 million to $200 million, indicating significant commercial potential.
How much money was raised and through what mechanism?
Nutriband raised $5,306,000 through the exercise of warrants at a strike price of $6.43 per share, providing immediate capital for their pharmaceutical development efforts.
What will the funds be used for specifically?
The proceeds will support the remaining clinical development of AVERSA Fentanyl and the submission of its New Drug Application with the U.S. Food and Drug Administration.
Where can investors find more information about Nutriband?
The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB, and the full press release can be viewed at https://ibn.fm/7olqo.
What makes AVERSA technology unique?
AVERSA™ technology can be incorporated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, representing an innovative approach to opioid safety.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 196392